ANGOAngioDynamics, Inc.
Is the price fair?
Priced for +44% a year vs −1% a year delivered. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~44% a year FCF growth. The price already bakes in strong, sustained growth.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What ANGO's price assumes
- Free cash flow yield
- 0.31%
Free cash flow yield · Medical Instruments & Supplies median 3.4%
- Growth the price implies
- +44%
Growth the price implies · The price pays for +44% free cash flow growth a year for a decade; revenue has grown −1.1% a year over the last three.
Details›
- EV / EBIToperating margin −11%: the multiple describes the denominator
- not meaningful
- Free cash flow, trailing twelve months
- $1.4M
- Market capitalisation
- $464M
- 3-year revenue growth
- −1.1%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Instruments & Supplies
Ranks #20 of 21 by RyuScore